CNS Drug Discoveries: Parkinson's disease

Table of Contents

Parkinson' s Disease

• EXECUTIVE SUMMARY

THE FACTS

• What is Parkinson' s disease and why are we interested in it?
• PATIENT STATISTICS
• Incidence, diagnosis rates and treatment; now and in the future
• PATIENT MODEL
• The treated PD patient population will grow by 3.6 percent per annum
• Summary of PD Patient Population Forecasts 2007A-2014E
• Model Assumptions
• DRUG GROWTH DRIVERS
• Potential Diagnostic Biomarkers for PD
• DRUG GROWTH RISKS/DAMPENERS

THE PD MARKET

• Global CNS Market 2007 (US$91.9 billion)
• PD Global Sales Split (2006)
• The Major Players
• Market Share of PD Players by Sales (Dec 2007A)
• Players and Products in 2014
• Market Share of PD Players by Sales (Dec 2014E)

CURRENT PD TREATMENTS

• Leading Brands
• Comparison of Leading PD Drug Classes
• Current Products' Patent Exposure
• Patent Exposure of Leading PD Brands
• ANALYSIS OF LEADING BRANDS
• Dopamine Agonists
• Apokyn
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Neupro
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Clinical Endpoint of Phase III trials with Neupro 1) Europe 2) the US
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Sifrol/Mirapex/Mirapexin
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Requip
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Monoamine Oxidase Inhibitors
• Azilect
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Catechol-O-Methyltransferase Inhibitors
• Comtan/Comtess/Stalevo
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A - 2014E
• Sales Forecasts of Current Leading PD Drugs
• Model Assumptions

NEW DRUGS IN R&D

• Drugs in Development to Treat PD
• ANALYSIS OF LATE-PHASE DRUGS
• New Drugs in Phase III Development to Treat PD
• Istradefylline
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Pardoprunox
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• Safinamide
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• GLOBAL SALES FORECASTS OF LATE-PHASE PD DRUGS 2009E- 2014E
• Sales Forecasts of Late-Phase Developmental PD Drugs
• Model Assumptions
• ANALYSIS OF PHASE II DRUGS
• New Drugs in Early Clinical Development to Treat PD
• Spheramine
• Novelty/rationale for mechanism of action
• Proof of concept/clinical data
• Management/clinical expertise
• Competition within the market-place/gaining share of voice
• Risks associated with developing a drug within a therapeutic class
• Filings and approval
• Sales forecasts and assumptions
• Competitor ratio analysis
• VR040

COMPETITOR RATIO ANALYSIS

• COMPETITOR RATIO ANALYSIS - PRODUCTS
• CR Analysis of PD Agents Approved by 2014 - Based on Drug Class
• COMPETITOR RATIO ANALYSIS - COMPANIES
• CR Analysis of PD Agents Approved by 2014 - Based on Company
• WINNERS & LOSERS
• Summary of Key Companies and Drugs in the PD Market by 2014

DISCON TINUATION OF DRUGS

• PD Drugs Discontinued from Clinical Development

PD APPENDIX 1

• Phase Transition Probability
• Probability of Launch

PD APPENDIX 2

• PD Patient Model
• Summary of PD Patient Population Forecasts

PD APPENDIX 3

• Global PD Drugs Sales 2007A-2014E
• Global PD Drug Sales 2007A-2014E

PD APPEN DIX 4

• Competitor Ratio Analysis Criteria
• Key PD Drugs on the Market by 2014

PARKINSON ' S DISEASE GLOSARY

PARKINSON ' S DISEASE REFERENCES

ACRONYMS